Levothyroxine treatment and pregnancy outcome in women with subclinical hypothyroidism undergoing assisted reproduction technologies: systematic review and meta-analysis of RCTs

BACKGROUND

Previous meta-analyses of observational data indicate that pregnant women with subclinical hypothyroidism have an increased risk of adverse pregnancy outcome. Potential benefits of levothyroxine (LT4) supplementation remain unclear, and no systematic review or meta-analysis of trial findings is available in a setting of assisted reproduction technologies (ART).

METHODS

Relevant trials published until August 2012 were identified by searching MEDLINE, EMBASE, Web of Knowledge, the Cochrane Controlled Trials Register databases and bibliographies of retrieved publications without language restrictions.

RESULTS

From 630 articles retrieved, we included three trials with data on 220 patients. One of these three trials stated ‘live delivery’ as outcome. LT4 treatment resulted in a significantly higher delivery rate, with a pooled relative risk (RR) of 2.76 (95% confidence limits 1.20–6.44; P = 0.018; I2 = 70%), a pooled absolute risk difference (ARD) of 36.3% (3.5–69.0%: P = 0.030) and a summary number needed to treat (NNT) of 3 (1–28) in favour of LT4 supplementation. LT4 treatment significantly lowered miscarriage rate with a pooled RR of 0.45 (0.24–0.82; P = 0.010; I2 = 26%), a pooled ARD of –31.3% (–48.2 to –14.5%: P < 0.001) and a summary NNT of 3 (2–7) in favour of LT4 supplementation. LT4 treatment had no effect on clinical pregnancy (RR 1.75; 0.90–3.38; P = 0.098; I2 = 82%). In an ART setting, no data are available on the effects of LT4 supplementation on premature delivery, arterial hypertension, placental abruption or pre-eclampsia.

CONCLUSIONS

Our meta-analyses provide evidence that LT4 supplementation should be recommended to improve clinical pregnancy outcome in women with subclinical hypothyroidism and/or thyroid autoimmunity undergoing ART. Further research is needed to determine pregnancy outcome after close monitoring of thyroid function to maintain thyroid-stimulating hormone and free T4 levels within the trimester-specific reference ranges for pregnancy.

Source:
http://humupd.oxfordjournals.org/cgi/content/short/19/3/251?rss=1

Granulocyte-colony stimulating factor for hematopoietic stem cell donation from healthy female donors during pregnancy and lactation: what do we know?

BACKGROUND

Hematopoietic growth factors (HGFs) are mostly used as supportive measures to reduce infectious complications associated with neutropenia. Over the past decade, the use of HGFs became a common method for mobilizing human CD34+ stem cells, either for autologous or allogeneic transplantation. However, since their introduction the long-term safety of the procedure has become a major focus of discussion and research. Most information refers to healthy normal donors and data concerning pregnant and lactating women are scarce. The clinical question, which is the core of this review, is whether stem cell donation, preceded by administration of granulocyte-colony stimulating factor (G-CSF) for mobilization, is a safe procedure for pregnant donors.

METHODS

Literature searches were performed in Pubmed for English language articles published before the end of May 2012, focusing on G-CSF administration during pregnancy, lactation and hematopoietic stem cell donation. Searches included animal and human studies.

RESULTS

Data from animals (n = 15 studies) and women (n = 46 studies) indicate that G-CSF crosses the placenta, stimulates fetal granulopoiesis, improves neonatal survival mostly for very immature infants, promotes trophoblast growth and placental metabolism and has an anti-abortive role. Granulocyte macrophage-CSF is a key cytokine in the maternal immune tolerance towards the implanted embryo and exerts protective long-term programming effects to preimplantation embryos. The available data suggest that probably CSFs should not be administered during the time of most active organogenesis (first trimester), except perhaps for the first week during which implantation takes place. Provided CSF is administered during the second and third trimesters, it appears to be safe, and pregnant women receiving the CSF treatment can become hematopoietic stem cell donors. There are also risks related to the anesthesia, which is required for the bone marrow aspiration. During lactation, there should be a period of at least 3 days to allow for clearance of CSF from milk before resuming breast feeding. With regard to teratogenicity or leukaemogenity, in non-pregnant or non-lactating women reports show that CSF administration is associated with a risk for leukemia; however, this risk is not higher compared with the control population.

CONCLUSIONS

The information available to date indicates that administration of CSF in general, and G-CSF in particular, is safe and healthy pregnant women can serve as donors of either bone marrow or peripheral blood stem cells. However, the clinical experience is rather limited and therefore until more data become available, G-CSF should not be used during pregnancy and lactation when other therapeutic options, instead of stem cell transplantation, are available.

Source:
http://humupd.oxfordjournals.org/cgi/content/short/19/3/259?rss=1

Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis

BACKGROUND

Oxidative stress might be associated with polycystic ovary syndrome (PCOS), but relatively small studies published to date do not permit reaching a definitive conclusion. We aimed at conducting a systematic review and meta-analysis of studies evaluating circulating markers of oxidative stress in patients with PCOS.

METHODS

We conducted a systematic review of studies reporting circulating markers of oxidative stress in women with PCOS and controls published up to June 2012, using Entrez PubMed and EMBASE online facilities. Meta-analysis calculated standardized mean differences (SMDs) and 95% confidence intervals (95CI).

RESULTS

From 1633 potential studies identified electronically, 68 studies, including 4933 PCOS patients and 3671 controls, were selected. For each of nine circulating markers of oxidative stress, an individual meta-analysis was conducted. Compared with control women, patients with PCOS presented higher circulating concentrations of homocysteine (23% increase, SMD 0.6, 95CI, 0.4–0.8), malondialdehyde (47% increase, SMD 1.9, 95CI 1.2–2.6) and asymmetric dimethylarginine (36% increase, SMD 1.1, 95CI 0.6–1.6), and increased superoxide dismutase activity (34% increase, SMD 1.0, 95CI 0.5–1.4) and decreased glutathione levels (50% decrease, SMD –3.7, 95CI –6.2 to –1.2) and paraoxonase-1 activity (32% decrease, SMD –0.9, 95CI –1.3 to –0.4). Similar results were found when restricting the analyses to studies in which patients and controls were matched for age and body mass index.

CONCLUSIONS

Circulating markers of oxidative stress are abnormal in women with PCOS independent of weight excess. This finding suggests that oxidative stress may participate in the pathophysiology of this common disorder.

Source:
http://humupd.oxfordjournals.org/cgi/content/short/19/3/268?rss=1

Genetic variants in pre-eclampsia: a meta-analysis

BACKGROUND

Pre-eclampsia has a clear familial component, suggesting that the condition may be partly attributable to genetic susceptibility. The search for susceptibility genes has led to a drastic increase in the number of published studies associating genetic factors with pre-eclampsia. However, attempts to replicate these findings have yielded inconsistent results. This meta-analysis assessed the pooled effect of each genetic variant that is reproducibly associated with pre-eclampsia.

METHODS

Studies that assessed the association between genes and pre-eclampsia were searched in PubMed, Embase and Web of Science. We selected all genetic variants that were significantly associated with pre-eclampsia in an initial study and were subsequently independently reproduced in at least one additional study. All studies that assessed these reproduced variants were then included. The association between genetic variants and pre-eclampsia was calculated at the allele level, and the main measure of effect was a pooled odds ratio in a random-effects model.

RESULTS

The literature search yielded 2965 articles, of which 542 investigated genetic associations in pre-eclampsia. We identified 22 replicated genetic variants, of which 7 remained significantly associated with pre-eclampsia following meta-analysis. These variants were in or near the following genes: ACE, CTLA4, F2, FV, LPL and SERPINE1.

CONCLUSIONS

This meta-analysis identified seven genetic variants associated with pre-eclampsia. Importantly, many of these variants are also risk factors for developing cardiovascular disease, revealing that pre-eclampsia and cardiovascular disease have shared genetic risk factors. The contribution of the identified genetic variants in the pathogenesis of pre-eclampsia should be the focus of future studies.

Source:
http://humupd.oxfordjournals.org/cgi/content/short/19/3/289?rss=1

Reproductive options for prospective parents in families with Huntington’s disease: clinical, psychological and ethical reflections

BACKGROUND

Huntington's disease (HD) is an autosomal dominant neurodegenerative late onset disorder. This review of reproductive options aims to increase reproductive confidence and to prevent suffering in relation to family planning around HD and possibly other late onset neurodegenerative disorders.

METHODS

Selected relevant literature and own views and experiences as clinical geneticists, psychologists and ethicists have been used.

RESULTS

Possible options, with emphasis on prenatal diagnosis (PD) and preimplantation genetic diagnosis (PGD) to prevent the transmission of HD to the next generation, are described and discussed. They are formally presented in a decision tree, taking into account the presence or absence of a fully penetrant allele (FPA), a reduced penetrant allele (RPA) or an intermediate allele (IA). A table compares invasive and non-invasive PD and PGD. From a psychological perspective, the complex process of counselling and decision-making regarding reproductive options is discussed. Special attention is paid to the decision to avoid the transmission of the mutation and to the confrontation and coping of a mutation-free child growing up with a parent developing disease symptoms. From an ethical point of view, reflections on both PD and PGD are brought forward taking into account the difference between FPA, RPA and IA, direct testing or exclusion testing and taking into account the welfare of the child in the context of medically assisted reproduction.

CONCLUSION

Recommendations and suggestions for good clinical practice in the reproductive care for HD families are formulated.

Source:
http://humupd.oxfordjournals.org/cgi/content/short/19/3/304?rss=1

Want to work for Chemistry World?

Have you ever wondered what it’d be like to come and work for us here at Chemistry World towers? If the thought has ever crossed your mind (or not, it doesn’t offend us if it hasn’t!) this could be your lucky day. We are currently advertising a couple of vacancies not to be missed. Whether you are new to the field of science communication, want to test whether this is the right career for you or you are an experienced journalist we’ve got something for everyone… Read on.

Business editor: We’re looking for an exceptional journalist, familiar with the chemical and pharmaceutical industry, to temporarily manage the business news section and regular business features.

For more info and to apply click here.

Science writer internship: The RSC is looking for a student member to work as a science writer in our editorial office this summer. You will gain experience working for two of our publications: Chemistry World and Education in Chemistry. This eight week position is supported by the Marriott Bequest Trust and will provide a hands-on introduction to the complete editorial process.

For more info and to apply click here. I recommend you also read Patrick’s blog here.

We’re looking for bright, ambitious people who are passionate about Chemistry World and communicating science. If that’s you, get in touch. Follow the links or, if you need more information, contact us at chemistryworld@rsc.org.

Bibiana Campos Seijo

Digg This  Reddit This  Stumble Now!  Share on Facebook  Bookmark this on Delicious  Share on LinkedIn  Bookmark this on Technorati  Post on Twitter  Google Buzz (aka. Google Reader)  

Source:
http://prospect.rsc.org/blogs/cw/2013/04/09/want-to-work-for-chemistry-world/

A Look Behind the Dissecting Art, Intersecting Anatomy Gallery Show

Dissecting Art; Intersecting Anatomy from Phillip Schalekamp on Vimeo.

Dissecting Art Video Phillip Schalekamp

Dissecting Art Video Vanessa Ruiz

Get an inside look at our recent gallery show Dissecting Art, Intersecting Anatomy: Merging Contemporary Art with the Works of Pauline Lariviere that opened March 9th, 2013 in Chicago. Hear curators Phillip Schalekamp and your very own Vanessa Ruiz talk about the significance of Pauline Lariviere’s gorgeous medical illustrations and the prevalence of women in medical art.

More photos of the awesome anatomical event! View all photos on the Dissecting Art Facebook page.

Dissecting Art Intersecting Anatomy gallery show Street Anatomy Chicago (5)

Dissecting Art Intersecting Anatomy gallery show Street Anatomy Chicago (6)

Dissecting Art Intersecting Anatomy gallery show Street Anatomy Chicago (4)

Dissecting Art Intersecting Anatomy gallery show Street Anatomy Chicago (3)

 

 

Source:
http://feedproxy.google.com/~r/streetanatomy/OQuC/~3/HxnK77tKW7M/

MISS Nutrition – Coach Luke McNally gives Ms Olympia Tegan Campbell a hiding in the gym! – Video


MISS Nutrition - Coach Luke McNally gives Ms Olympia Tegan Campbell a hiding in the gym!
07/04/13 - 13 weeks out from her Pro Debut. Tegan Campbell trains legs with MISS Nutrition head coach Luke McNally. Lying Hamstring Curls - 4 sets of 12 Spli...

By: massnutritionoz

Original post:
MISS Nutrition - Coach Luke McNally gives Ms Olympia Tegan Campbell a hiding in the gym! - Video

DSM and Republic of Tatarstan sign MOU for fortified nutrition

Royal DSM, the global Life Sciences and Materials Sciences company, announces today that it has signed a Memorandum of Understanding (MOU) for a strategic partnership with the Ministry of Health Care of the Republic of Tatarstan with the aim of modernizing the Republic`s public health sector through fortified nutrition. The MOU was signed today in Amsterdam (Netherlands) in the presence of President Vladimir Putin of the Russian Federation and Prime Minister Mark Rutte of the Netherlands.

Under the terms of the MOU, DSM and the Ministry of Health Care of the Republic of Tatarstan will implement a study for the provision of vitamins to patients (children and adults) admitted for treatment to in-patient hospitals to measure the effectiveness of a specially developed vitamin and mineral complex. Following a positive outcome, the objective is to start adding vitamins/minerals when providing in-patient medical care in hospitals in the Republic of Tatarstan.

The strategic partnership between DSM and the Republic of Tatarstan has been developed within the framework of cooperation between the Russian Federation and the Netherlands. The Russian Federation`s Healthy Nutrition strategy for 2020 aims at preserving and strengthening public health and preventing of nutrition related diseases. It has been concluded that based on the current demographic situation in the Russian Federation, a change in nutrition patterns is needed to increase the life expectancy of the Russian population.

Rustam Minnikhanov, President of the Republic of Tatarstan, said: "On behalf of the Republic of Tatarstan I fully support DSM in its efforts to further develop its successful cooperation that started in 2010 in Naberezhnye Chelny with the production of animal nutrition. Full and regular supply of the body with vitamins, minerals and trace elements is one of the key factors in maintaining health. This joint project of DSM, the Institute of Nutrition and the Ministry of Health will enable the introduction of preventive fortification as a standard provision of medical assistance in the hospitals of the Republic."

Feike Sijbesma, Chief Executive Officer and Chairman of the DSM Managing Board, said: "As the world`s largest producer of micronutrients, DSM has the expertise and resources needed to support an effective governmental food fortification program. An insufficient vitamin A intake can have a negative effect on the efficiency of hospital treatment, but also lowers patients` resistance. I am proud that we will work with the Ministry of Health Care in Tatarstan to begin to reduce vitamin deficiencies and subsequently increase life expectancy and I hope we will be able to expand this initiative to other regions of the Russian Federation."

For DSM, Russia is one of the High Growth Economies the company is focusing on in executing its strategy DSM in motion: driving focused growth. DSM`s main business areas in Russia are food and feed ingredients, pharmaceutical intermediate products, biotechnology, UHMWPE-based materials, resins and engineering plastics. Through its business activities, DSM meets the needs and trends in the Russian Federation. In 2012, DSM celebrated 20 years of presence in Russia.

In 2010 DSM started a joint venture in Tatarstan to contribute to Russia`s goal of reaching a higher self-sufficiency in animal protein production and supply by securing better animal nutrition. In 2011 DSM entered into a long-term partnership in the area of engineering plastics with JSC KuibyshevAzot in Tolyatti (Samara Region) in order to supply locally produced products to the automotive and electrical & electronics industries.

DSM - Bright Science. Brighter Living.(TM) Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM`s 23,500 employees deliver annual net sales of around 9 billion. The company is listed on NYSE Euronext. More information can be found at http://www.dsm.com.

For more information:

The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Here is the original post:
DSM and Republic of Tatarstan sign MOU for fortified nutrition

Leading nutrition organizations issue call to prioritize child nutrition for a healthier, more prosperous Asia

As government, medical, academic and industry representatives gather at the first regional World Health Summit in Singapore, a group of nutrition organizations including global non-government organizations and Royal DSM called for urgent action to ensure adequate nutrition for children in their first 1,000 days of life.

A third of all children in Asia are stunted, or too short for their age - a key indicator of chronic malnutrition. Malnutrition during a child`s critical early years damages their intellectual and physical development, limiting their future economic participation, and increases their vulnerability to non-communicable diseases (NCDs) in adulthood. The World Bank estimates that India, where 48% of children are stunted and over 30% of children are born with a low birth weight, loses approximately 3% of annual GDP due to malnutrition.

The nutrition group, which includes World Vision, Save the Children, the Global Alliance for Improved Nutrition (GAIN), the Essential Micronutrients Foundation and industry partner Royal DSM, called on Summit delegates to commit to nutrition support as a key input to sustainable health and economic development outcomes. It called on governments to promote adequate health and nutrition for women of reproductive age, particularly pregnant and lactating women, to ensure their children have a head-start in good nutritional status. Through public-private partnerships, the private sector can support countries in improving diets by fortifying staples and making vitamin and mineral supplements affordable to the poor.

"The nutritional challenges faced by millions of children across Asia, coupled with increased economic inequality, can only be tackled through strong public-private partnerships. This combination of expertise and experience, with a profound sense of responsibility, are the very best tools we have for ridding the world of malnutrition," said Stephan Tanda, Managing Board Member of Royal DSM, on behalf of the group, adding that it welcomed interest and participation from key stakeholders across both sectors.

Singapore`s successes in maternal and child health can serve as a model for other countries. Since its independence, the country has achieved one of the lowest infant and under-five mortality rates in the world. With its strategic location and regional hub status in Asia, Singapore can play an important role in fostering greater public-private partnerships in the region to improve nutrition in the first 1,000 days.

Malnutrition is associated with poor feeding practices and other lack of access clean water, sanitation, healthcare, social protection and initiatives to empower women. There is compelling evidence connecting maternal nutrition to increased risks in their offspring of developing chronic disease, particularly diabetes and heart disease, later in life. Both undernutrition and overnutrition can have long term adverse effects. Of particular concern is the rapidly rising incidence of gestational diabetes and maternal obesity in Asia, which has major implications for the next generation.

"Economic growth alone will not solve the world`s nutrition problems - political leadership is absolutely necessary," asserted the group. "Governments must understand that investing in both mother and child nutrition, especially in the first 1000 days, means investing in their country`s economic future."

For more information:

DSM - Bright Science. Brighter Living.(TM) Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM`s 23,500 employees deliver annual net sales of about 9 billion. The company is listed on NYSE Euronext.

Global Alliance for Improved Nutrition (GAIN) Driven by a vision of a world without malnutrition, GAIN was created in 2002 at a Special Session of the U.N. General Assembly on Children. GAIN supports public-private partnerships to increase access to the missing nutrients in diets necessary for people, communities and economies to be stronger and healthier. With a current daily reach of over 667 million people in more than 30 countries, GAIN`s goal is to improve the lives of one billion people by 2015 within the most vulnerable populations around the world through access to sustainable nutrition solutions. Website: http://www.gainhealth.org/

View original post here:
Leading nutrition organizations issue call to prioritize child nutrition for a healthier, more prosperous Asia

Herbalife Becomes First Official Nutrition Sponsor of the 2013 Billboard Latin Music Conference and Awards

LOS ANGELES--(BUSINESS WIRE)--

Herbalife (HLF) announced an exclusive nutrition sponsorship deal with Latin musics premier event, the Billboard Latin Music Conference and Awards taking place in Miami on April 22-25.

As official nutrition sponsor of the Billboard Latin Music Conference and Awards, Herbalife will supply all attendees, speakers and artists with nutritious snacks such as protein bars, hydration and energy drinks throughout the event. Herbalife products will also be available at the VIP lounge for conference panelists at the JW Marriott Marquis, and at the Artist Gifting Suite at the BankUnited Center in Miami.

The 2013 Billboard Latin Music Conference and Awards Presented by State Farm in Association with Pepsi features three days of provocative presentations and panel discussions, exclusive Q&As, never-before-heard case studies from the biggest brands and digital marketers; cutting-edge artist showcases featuring some of the hottest acts; and access to parties and networking opportunities with senior executives and artists who are moving the industry forward. Registration to the Conference also includes access to the Billboard BASH a pre-Billboard Latin Music Awards party featuring performances by some of this years finalists - and The Billboard Latin Music Awards Presented by State Farm. The Billboard Latin Music Awards, produced and broadcast live by Telemundo, is the only recognition that truly reflects the best in Latin music, as determined by actual sales and radio play. For more information, please visit: http://www.BillboardLatinConference.com, or follow the event on: Facebook/Billboard and Twitter: @Billboard with the hashtag #BBLATIN.

We are truly excited about partnering this year with the Billboard Latin Music Conference and Awards and introducing our brand and our line of products to the Latin music community. We believe its a great fit and look forward to continue promoting a healthy lifestyle and keeping all conference attendees and talent properly hydrated and energized throughout the conference and during rehearsals, stated Ibi Fleming, senior vice president and managing director, Herbalife North America.

Herbalife, a global nutrition company that sells weight management, nutrition, and personal care products intended to support a healthy lifestyle, has traditionally been associated with sports sponsorships such as the Los Angeles Galaxy, FC Barcelona and Leo Messi. With this new agreement, Herbalife is expanding its brand awareness and exposure to the Latin music industry and hundreds of music professionals, including radio programmers and top recording Latin artists.

Having Herbalife join this years line of partners as official nutrition sponsor is a perfect match for our event, said Cebele Marquez, Sponsorship and Business Development Manager. We want to ensure that our conference attendees, speakers and participating artists stay healthy and properly energized during the multiple panel sessions and events leading up to the awards show on April 25. Were delighted to welcome Herbalife as a sponsor and look forward to a great program.

Herbalife also sponsors over 100 sporting events, teams and athletes around the world that reflect the companys commitment to a healthy active life supported by good nutrition. These sponsorships include the Herbalife Los Angeles Triathlon, and Pumas soccer club in Mexico.

About Herbalife Ltd.

Herbalife Ltd. (HLF) is a global nutrition company that sells weight management, nutrition and personal care products intended to support a healthy lifestyle. Herbalife products are sold in more than 80 countries to and through a network of independent distributors. The company supports the Herbalife Family Foundation and its Casa Herbalife program to help bring good nutrition to children. Herbalife's website contains information about Herbalife, including financial and other information for investors at http://ir.Herbalife.com. The company encourages investors to visit its website from time to time, as information is updated and new information is posted.

Read more:
Herbalife Becomes First Official Nutrition Sponsor of the 2013 Billboard Latin Music Conference and Awards

Bref. Nous sommes Technico-Commerciaux en Instrumentation Biotechnologique et Biomédicale! – Video


Bref. Nous sommes Technico-Commerciaux en Instrumentation Biotechnologique et Biomédicale!
Présentation de la licence pro TCIBB, réalisée par la promo TCIBB 2012-2013. Pour tout renseignement : caroline.norez@univ-poitiers.fr.

By: Caroline Norez

Go here to read the rest:
Bref. Nous sommes Technico-Commerciaux en Instrumentation Biotechnologique et Biomédicale! - Video

CML HealthCare Inc. to Install North America’s First and World’s Largest Fully Automated BD Kiestraâ„¢ Microbiology …

MISSISSAUGA, Ontario, April 8, 2013 /PRNewswire/ --CML HealthCare Inc. (CLC.TO) (the "Company" or "CML"), a leading community-based provider of laboratory and medical imaging services in Ontario and British Columbia, and BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, today announced an agreement for CML to install two BD Kiestra Total Laboratory Automation ("TLA") systems. This fully automated microbiology system will be installed at CML's central laboratory by the third quarter of 2013. The BD Kiestra TLA system is designed to significantly increase overall microbiology lab productivity, streamline workflow, and shorten the time to results.

"We are very excited to be the first laboratory services provider in North America to be installing the BD Kiestra TLA system. With our central laboratory processing approximately three million microbiology tests annually, this installation will be the largest in the world for the BD Kiestra TLA system," said Thomas Wellner, President and CEO of CML. "The implementation of the BD Kiestra TLA system will allow CML to increase our capacity, reduce result turnaround times, and contribute to the growth of our core laboratory business. It will provide us with a significant competitive advantage and support a key pillar of our growth strategy which is to establish innovative hospital and other partnerships."

BD Kiestra TLA system automates the manual processes associated with inoculating and incubating microbiology specimens, and uses digital imaging of the inoculated specimens to shorten the time to detect bacterial growth. The increased efficiency, and quality improvements associated with automation allow for faster delivery of more accurate results to provide optimal patient care. In addition, laboratory staff is able to devote more time to analytical and value-added tasks.

"BD is proud to be working with CML HealthCare Inc., one of Canada's largest and most forward-looking laboratory services providers," said Tom Polen, President, BD Diagnostics - Diagnostic Systems. "Rapid diagnosis and treatment of infections is critical; however, many of the traditional testing protocols take two or three days to generate an actionable result.Using the BD Kiestra TLA system, integrated with other rapid diagnostic technologies, CMLwill be a pioneer in implementing technology that can often reduce those times significantly. We expect this to enable clinicians to provide patients with the most effective treatment earlier thus improving the standard of care and avoiding unnecessary healthcare costs."

The BD Kiestra TLA system currently has an installation base of instruments at public hospitals, universities, and privately owned laboratories in more than eleven countries worldwide since its introduction in 2006.

About CML HealthCare Inc.

Based in Mississauga, Ontario, CML HealthCare Inc. is a leading community-based, medical diagnostic services provider in Canada operating 114 Client C.A.R.E. Centres in Ontario, 84 imaging centres in Ontario and British Columbia, and a reference laboratory in Ontario focused on specialized coagulation testing and equipment calibration for international customers. CML is publicly-traded on the Toronto Stock Exchange under the symbol "CLC" and has approximately 89.8 million common shares outstanding. For more information, please visit http://www.cmlhealthcare.com or follow CML on Twitter @cmlhealthcare.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit http://www.bd.com.

For more information, please contact:

Read the original here:
CML HealthCare Inc. to Install North America's First and World's Largest Fully Automated BD Kiestraâ„¢ Microbiology ...

CML HealthCare Inc. to Install North America’s First and World’s Largest Fully Automated BD Kiestra(TM) Microbiology …

MISSISSAUGA, ONTARIO--(Marketwired - Apr 8, 2013) - CML HealthCare Inc. (CLC.TO) (the "Company" or "CML"), a leading community-based provider of laboratory and medical imaging services in Ontario and British Columbia, and BD (Becton, Dickinson and Company) ("BD"), a leading global medical technology company, today announced an agreement for CML to install two BD Kiestra Total Laboratory Automation ("TLA") systems. This fully automated microbiology system will be installed at CML's central laboratory by the third quarter of 2013. The BD Kiestra TLA system is designed to significantly increase overall microbiology lab productivity, streamline workflow, and shorten the time to results.

"We are very excited to be the first laboratory services provider in North America to be installing the BD Kiestra Total Laboratory Automation system. With our central laboratory processing approximately three million microbiology tests annually, this installation will be the largest in the world for the BD Kiestra TLA system," said Thomas Wellner, President and CEO of CML. "The implementation of the BD Kiestra TLA system will allow CML to increase our capacity, reduce result turnaround times, and contribute to the growth of our core laboratory business. It will provide us with a significant competitive advantage and support a key pillar of our growth strategy which is to establish innovative hospital and other partnerships."

BD Kiestra TLA system automates the manual processes associated with inoculating and incubating microbiology specimens, and uses digital imaging of the inoculated specimens to shorten the time to detect bacterial growth. The increased efficiency, and quality improvements associated with automation allow for faster delivery of more accurate results to provide optimal patient care. In addition, laboratory staff is able to devote more time to analytical and value-added tasks.

"BD is proud to be working with CML HealthCare Inc., one of Canada's largest and most forward looking laboratory services provider," said Tom Polen, President BD Diagnostics - Diagnostic Systems. "Rapid diagnosis and treatment of infections is critical; however, many of the traditional testing protocols take two or three days to generate an actionable result. Using the BD Kiestra TLA system, integrated with other rapid diagnostic technologies, CML will be a pioneer in implementing technology that can often reduce those times significantly. We expect this to enable clinicians to provide patients with the most effective treatment earlier - thus improving the standard of care and avoiding unnecessary healthcare costs."

The BD Kiestra TLA System currently has an installation base of instruments at public hospitals, universities, and privately owned laboratories in more than eleven countries worldwide since its introduction in 2006.

About CML HealthCare Inc.

Based in Mississauga, Ontario, CML HealthCare Inc. is a leading community-based, medical diagnostic services provider in Canada operating 114 Client C.A.R.E. Centres in Ontario, 84 imaging centres in Ontario and British Columbia, and a reference laboratory in Ontario focused on specialized coagulation testing and equipment calibration for international customers. CML is publicly-traded on the Toronto Stock Exchange under the symbol "CLC" and has approximately 89.8 million common shares outstanding. For more information, please visit http://www.cmlhealthcare.com or follow CML on Twitter @cmlhealthcare.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit http://www.bd.com.

Visit link:
CML HealthCare Inc. to Install North America's First and World's Largest Fully Automated BD Kiestra(TM) Microbiology ...

New mouse viruses could aid hepatitis research

Public release date: 9-Apr-2013 [ | E-mail | Share ]

Contact: Jim Sliwa jsliwa@asmusa.org 202-942-9297 American Society for Microbiology

Newly discovered mouse viruses could pave the way for future progress in hepatitis research, enabling scientists to study human disease and vaccines in the ultimate lab animal. In a study to be published in mBio, the online open-access journal of the American Society for Microbiology, scientists describe their search for viruses related to the human hepatitis C virus (HCV) and human pegiviruses (HPgV) in frozen stocks of wild mice. The discovery of several new species of hepaciviruses and pegiviruses that are closely related to human viruses suggests they might be used to study these diseases and potential vaccines in mice, without the need for human volunteers.

About 2% of the population is infected with the hepatitis C virus and 5% is infected with human pegiviruses, but it's been difficult to study new drugs or develop vaccines against these infections because the human strains do not infect animals that can be studied in the lab. Lead author Amit Kapoor of Columbia University says it surprised him to find similar viruses in mice.

"People have been waiting for decades to find something like this. It was shocking for me to see that the viruses are there and there are so many of them," says Kapoor.

Kapoor and his colleagues screened an archive of more than 400 frozen rodents, mostly deer mice, for viruses related to the human hepatitis C virus and human pegiviruses. The search turned up a number of candidates, and they selected two for complete genome sequencing: a rodent hepacivirus (RHV) found in deer mice and a rodent pegivirus (RPgV) found in a white-throated woodrat. Sequencing confirmed that the viruses are very closely related to human strains but they represent several novel species in the Hepacivirus and Pegivirus genera within the family Flaviviridae.

These rodent viruses have genes, proteins, and translational elements that closely mirror those found in human hepaciviruses and pegiviruses, suggesting they have great potential for use in the lab. Animal models of hepatitis would help scientists explore the ways these viruses causes disease and aid in the design of treatments and vaccines. Human pegiviruses, on the other hand, have unknown effects, so studying how they work in rodents could well point the way to what they might do in the human body and why so many people are infected.

Kapoor's lab is now focused on exploring the biology of these viruses. "We are trying to infect deer mice, to study biological properties of these hepatitis C-like viruses," says Kapoor. "And if we find one of these viruses is hepatotrophic [having an attraction to the liver] and causes disease similar to hepatitis C, that would be a big step forward in understanding hepatitis C-induced pathology in humans."

###

mBio is an open access online journal published by the American Society for Microbiology to make microbiology research broadly accessible. The focus of the journal is on rapid publication of cutting-edge research spanning the entire spectrum of microbiology and related fields. It can be found online at http://mbio.asm.org.

More here:
New mouse viruses could aid hepatitis research